Recruiting × Interventional × Liver Neoplasms × Clear all
NCT06673329 2026-05-13

Brodalumab in the Treatment of Immune-Related Adverse Events

Columbia University

Phase 1 Recruiting
11 enrolled
NCT06239194 2026-05-06

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
285 enrolled
NCT04907643 2026-02-20

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Cedars-Sinai Medical Center

Phase NA Recruiting
360 enrolled
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled